EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 15th, 2024 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (this “Agreement”) is made and entered into this 31st day of October, 2023 (the “Effective Date”) by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Esther Rajavelu (“Executive”).
AMENDMENT 3 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 15th, 2024 • Spero Therapeutics, Inc. • Pharmaceutical preparations
This Amendment 3 (“Amendment 3”) entered into as of the last date of the signatures below (“Amendment 3 Effective Date”), by and between Spero Therapeutics, Inc. (“Spero”) and GlaxoSmithKline (“GSK”), hereby amends the Exclusive License Agreement between the Parties dated September 21, 2022, as amended on July 4, 2023, by Amendment 1 to Exclusive License Agreement and further amended on December 20, 2023, by Amendment 2 to Exclusive License Agreement (the “Agreement”). Capitalized terms not otherwise defined in this Amendment 3 will have the same meanings as ascribed to such terms in the Agreement.
